dc.creator | Koshak, Abdulrahman E. | |
dc.creator | Koshak, Emad A. | |
dc.date.accessioned | 2020-08-26T14:49:18Z | |
dc.date.available | 2020-08-26T14:49:18Z | |
dc.date.created | 2020 | |
dc.identifier.issn | 0011-393X | spa |
dc.identifier.other | https://doi.org/10.1016/j.curtheres.2020.100602 | spa |
dc.identifier.uri | http://hdl.handle.net/20.500.12010/12300 | |
dc.description.abstract | Background
Coronaviruses are responsible for several human diseases such as the pandemic infectious
disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2). Nigella sativa (NS) is a natural food supplement with a known
safety profile that may provide a wealth of known antiviral compounds.
Objective
To explore the studies supporting the NS potential for hitting SARS-CoV-2 targets.
Methods A literature search for scientific published or preprint in-silico studies between 1990 and 2020 in
electronic databases (PubMed, Science Direct, Scopus, and Google Scholar) was performed for
the terms Nigella sativa, black seed, coronavirus, SARS-CoV-2 and COVID-19.
Results
At least eight in-silico studies have shown that some compounds of NS, including Nigelledine,
α-Hederin, Hederagenin, Thymohydroquinone, and Thymoquinone, had high to moderate
affinity with SARS-CoV-2 enzymes and proteins. These compounds may potentially inhibit
SARS-CoV-2 replication and attachment to host cell receptors.
Conclusions
These preliminary data propose NS as a potential phytotherapy candidate for COVID-19. Further
preclinical experimental evidence is required followed by a phase 1 clinical trial.
Keywords: SARS-CoV-2; COVID-19; Coronavirus; In-silico; Nigella sativa
Running Title: Nigella sativa in COVID-19 | spa |
dc.format.extent | 13 páginas | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | Current Therapeutic Research | spa |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
dc.subject | COVID-19 | spa |
dc.subject | Potential phytotherapy | spa |
dc.title | Nigella sativa l. as a potential phytotherapy for covid-19: A mini-review of in-silico studies | spa |
dc.type.local | Artículo | spa |
dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
dc.subject.lemb | COVID-19 | spa |
dc.subject.lemb | SARS-CoV-2 | spa |
dc.subject.lemb | Coronavirus | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
dc.rights.local | Abierto (Texto Completo) | spa |
dc.identifier.doi | https://doi.org/10.1016/j.curtheres.2020.100602 | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |